Skip to Main content Skip to Navigation
Journal articles

Induction of multiple CD8+ T cell responses against the inducible Hsp70 employing an Hsp70 oligoepitope peptide.

Abstract : The inducible heat shock protein Hsp70 has been described as a tumour antigen being frequently overexpressed in tumours of various histologic origins, with a role in tumourigenicity, as a critical event in tumour progression. A strategy to enhance the immune response to an antigen is the identification of multiple epitopes and the induction of a polyspecific response. Applied to tumour vaccination, such a polyspecific response should lead to a more robust antitumour efficacy. The long peptide Hsp70380-402 encompasses three nonamer peptides with a high affinity for HLA-A *0201. In a previous paper, we have shown that two of these nonamer peptides, p391 and p393, can raise CTL to recognize tumour cells overexpressing Hsp70. In the present paper, we demonstrate that the third nonamer peptide, p380, is a new epitope efficient in raising an antitumour immune response. The p380-402 polypeptide was able to induce an immune response against each of the three constituent epitopes both in vivo in HLA-A *0201 transgenic mice and in vitro with human PBMC. This polypeptide therefore constitutes an interesting candidate for the induction of multiple HLA-A *0201-restricted anti-Hsp70 antitumour CTL responses.
Document type :
Journal articles
Complete list of metadatas

https://hal-pasteur.archives-ouvertes.fr/pasteur-00166658
Contributor : François Lemonnier <>
Submitted on : Wednesday, August 8, 2007 - 12:10:02 PM
Last modification on : Wednesday, October 14, 2020 - 4:01:54 AM

Links full text

Identifiers

Collections

Citation

Olivier Faure, Stéphanie Graff-Dubois, Pedro M S Alves, Sébastien Cornet, Marie-Thérèse Duffour, et al.. Induction of multiple CD8+ T cell responses against the inducible Hsp70 employing an Hsp70 oligoepitope peptide.. Oncology Reports, Spandidos Publications, 2007, 17 (3), pp.679-85. ⟨10.3892/or.17.3.679⟩. ⟨pasteur-00166658⟩

Share

Metrics

Record views

425